Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
PJK Van Meer, M Kooijman, V Brinks… - MAbs, 2013 - Taylor & Francis
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
PJK van Meer, M Kooijman, V Brinks… - …, 2013 - pubmed.ncbi.nlm.nih.gov
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
PJ van Meer, M Kooijman, V Brinks… - Mabs, 2013 - europepmc.org
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
[HTML][HTML] Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
PJK van Meer, M Kooijman, V Brinks… - mAbs, 2013 - ncbi.nlm.nih.gov
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment
D Conrado, J Larkindale, A Berg, M Hill, J Burton… - mAbs, 2013 - hero.epa.gov
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.
PJ van Meer, M Kooijman, V Brinks… - Mabs, 2013 - europepmc.org
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …
challenge in drug development. Non-human primates (NHPs) are often the only relevant …